From goblet cells to gut health: the role of AGR2 and mucus

The AGR2 protein plays a pivotal role in regulating intestinal mucus production through its interaction with IRE1β, revealing a crucial mechanism for maintaining a healthy gut environment

Goblet cells are specialized cells in the intestine that are crucial for maintaining a healthy gut environment. A new study by the team of Prof. Sophie Janssens and the lab of Prof. Savvas Savvides (VIB-UGent Center for Inflammation Research), together with the team of Prof. Sven Eyckerman (VIB-UGent Center for Medical Biotechnology) reveals the important role of the protein AGR2 in regulating the intestinal mucus layer. Their work appears in The EMBO Journal.

A healthy intestinal ecosystem

The human intestine is a bustling ecosystem teeming with diverse cell types, each with its unique role in maintaining the delicate balance essential for overall well-being. Goblet cells, in particular, play a vital role in safeguarding the intestinal environment by producing and secreting mucins, the main components of mucus. This mucus layer acts as a protective barrier that shields the intestinal lining from harmful pathogens and ensures a harmonious relationship with the trillions of microbes that call the gut home.

Dr. Eva Cloots (VIB-UGent), first author of the study: "We knew that the protein AGR2 was involved in the proper folding and secretion of mucin proteins within goblet cells, but the exact mechanism through which AGR2 does this were unknown. We decided to focus on the interplay between AGR2 and IRE1β, a sensor that responds to cellular stress caused by mis- or unfolded proteins."

And that turned out to be a key insight. The team discovered that AGR2 acts as a key regulator of IRE1β, modulating its activity and, in turn, this affects the production and secretion of mucins by goblet cells. By binding to IRE1β, AGR2 'tunes' the cellular stress response, ensuring that the delicate balance of mucin production is maintained.

Prof. Sophie Janssens (left) and Dr. Eva Cloots (right).

Mucus and mutations

Mutations in the AGR2 protein have recently been identified and are linked with inflammatory bowel disease-like symptoms. The researchers show how such a mutated AGR2 fails to bind with IRE1β, which leads to the stress sensor being 'on' the whole time. As a result, mucin (and mucus) production and maintenance suffer and gut inflammation follows.

Prof. Sophie Janssens (VIB-UGent): "Understanding the effects of mutations in AGR2 might lead to new avenues for understanding and potentially treating conditions characterized by gut inflammation. Our work, however, also provides basic knowledge on the intricate interplay between cellular stress responses and the maintenance of tissue homeostasis."

With AGR2 revealed as a missing puzzle piece to ensure healthy intestinal mucus, the researchers are keen to pursue open questions about the interactions between AGR2 and IRE1β and their importance proper folding of mucin proteins.

Structure of the AGR2 protein, highlighting locations known to be affected by specific mutations.

This work was supported by VIB, FWO, UGent, and the Medical Research Council DTP.


Publication

Cloots et al. Activation of goblet-cell stress sensor IRE1β is controlled by the mucin chaperone AGR2. The EMBO Journal, 2024.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be
Website preview
Brain immune cells may help build Alzheimer’s plaques
A new study led by researchers from VIB and KU Leuven shows that immune cells called microglia can actively promote the formation of plaques in Alzheimer’s disease, challenging the long-standing view that these cells serve only as defenders against plaque buildup. The findings were recently published in PNAS.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be